HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Com. Kessler resignation may bode well for FDA reform activity in 1997.

This article was originally published in The Rose Sheet

Executive Summary

FDA REFORM LEGISLATION MAY BE MORE FEASIBLE WITH KESSLER RESIGNATION: Commissioner David Kessler's Nov. 25 announcement that he plans to resign increases the likelihood that the Administration will forward its own FDA reform legislative proposal in 1997. Congress also has indicated that it plans to address FDA reform during the 105th session.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS003499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel